SCHEMBL3013054

SCHEMBL3013054

CC(C)c1cc(C(C)C)c(S(=O)(=O)N2CCN(c3nc(-c4ccc(Cl)cc4Cl)cs3)CC2)c(C(C)C)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.54
FABP4 P15090 2/20 0.44
MAPT P10636 6/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
ALDH1A1 P00352 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
LMNA P02545 5/20 0.41
MAPK1 P28482 3/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
NPSR1 Q6W5P4 2/20 0.40
USP2 O75604 1/20 0.38
RECQL P46063 1/20 0.38
HSD17B10 Q99714 1/20 0.38
POLB P06746 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3654626 0.90 AR (0.45) ARFABP4MAPTSMN1; SMN2ALDH1A1
SCHEMBL3011298 0.89 MAPT (0.55) ARFABP4MAPTSMN1; SMN2ALDH1A1
SCHEMBL3014519 0.86 AR (0.52) ARFABP4MAPTSMN1; SMN2LMNA
SCHEMBL3009218 0.85 SMN1; SMN2 (0.45) ARFABP4MAPTSMN1; SMN2ALDH1A1
SCHEMBL3012949 0.84 LMNA (0.46) ARMAPTSMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL3018623 0.84 AR (0.53) ARMAPTSMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL3005463 0.83 FABP4 (0.43) ARFABP4MAPTSMN1; SMN2ALDH1A1
SCHEMBL3001185 0.83 SMN1; SMN2 (0.51) ARFABP4MAPTSMN1; SMN2ALDH1A1
SCHEMBL3018508 0.83 AR (0.55) ARFABP4MAPTSMN1; SMN2ALDH1A1
SCHEMBL3021331 0.82 MAPK1 (0.62) ARMAPTSMN1; SMN2ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885FABP4 3254/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.